HC Wainwright Brokers Decrease Earnings Estimates for BHST

BioHarvest Sciences Inc. (NASDAQ:BHST) – Equities researchers at HC Wainwright reduced their Q2 2026 earnings per share estimates for BioHarvest Sciences in a research note issued on Friday, May 15th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings of ($0.14) per share for the quarter, down from their prior forecast of ($0.09). The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.46) EPS, FY2027 earnings at ($0.16) EPS and FY2029 earnings at $0.83 EPS.

A number of other equities research analysts have also issued reports on BHST. Roth Mkm initiated coverage on BioHarvest Sciences in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $10.00.

BioHarvest Sciences Stock Down 3.4%

Shares of BioHarvest Sciences stock opened at $3.96 on Tuesday. The stock’s fifty day moving average is $4.25 and its 200-day moving average is $5.21. The firm has a market capitalization of $77.68 million, a PE ratio of -6.71 and a beta of 0.81. The company has a quick ratio of 3.38, a current ratio of 3.97 and a debt-to-equity ratio of 0.10. BioHarvest Sciences has a 12-month low of $3.57 and a 12-month high of $12.80.

BioHarvest Sciences (NASDAQ:BHST) last announced its earnings results on Thursday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $8.51 million for the quarter, compared to analyst estimates of $8.50 million. BioHarvest Sciences had a negative return on equity of 102.36% and a negative net margin of 32.54%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BHST. King Luther Capital Management Corp purchased a new position in shares of BioHarvest Sciences during the fourth quarter valued at $208,000. Geode Capital Management LLC purchased a new position in shares of BioHarvest Sciences during the fourth quarter valued at $61,000. Thompson Siegel & Walmsley LLC purchased a new position in shares of BioHarvest Sciences during the fourth quarter valued at $1,945,000. HRT Financial LP purchased a new position in shares of BioHarvest Sciences during the fourth quarter valued at $75,000. Finally, Jane Street Group LLC purchased a new position in shares of BioHarvest Sciences during the fourth quarter valued at $145,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.